BRPI0817200A2 - composições oftálmicas sólida e uso de compostos para fabricação de medicamento - Google Patents

composições oftálmicas sólida e uso de compostos para fabricação de medicamento

Info

Publication number
BRPI0817200A2
BRPI0817200A2 BRPI0817200A BRPI0817200A BRPI0817200A2 BR PI0817200 A2 BRPI0817200 A2 BR PI0817200A2 BR PI0817200 A BRPI0817200 A BR PI0817200A BR PI0817200 A BRPI0817200 A BR PI0817200A BR PI0817200 A2 BRPI0817200 A2 BR PI0817200A2
Authority
BR
Brazil
Prior art keywords
ophthalmic compositions
pharmaceutical manufacturing
manufacturing compounds
solid ophthalmic
solid
Prior art date
Application number
BRPI0817200A
Other languages
English (en)
Inventor
L Edelman Jeffrey
M Harrison Kelly
T Spada Lon
M Hughes Patrick
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0817200A2 publication Critical patent/BRPI0817200A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
BRPI0817200A 2007-09-21 2008-09-18 composições oftálmicas sólida e uso de compostos para fabricação de medicamento BRPI0817200A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/859,627 US20090082321A1 (en) 2007-09-21 2007-09-21 Steroid containing drug delivery systems
PCT/US2008/076837 WO2009039262A2 (en) 2007-09-21 2008-09-18 Steroid containing ophthalmic drug delivery systems

Publications (1)

Publication Number Publication Date
BRPI0817200A2 true BRPI0817200A2 (pt) 2017-01-31

Family

ID=40409724

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817200A BRPI0817200A2 (pt) 2007-09-21 2008-09-18 composições oftálmicas sólida e uso de compostos para fabricação de medicamento

Country Status (7)

Country Link
US (3) US20090082321A1 (pt)
EP (1) EP2200581A2 (pt)
JP (2) JP2010540447A (pt)
AU (1) AU2008302309B2 (pt)
BR (1) BRPI0817200A2 (pt)
CA (1) CA2700072C (pt)
WO (1) WO2009039262A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US20100098772A1 (en) * 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100278897A1 (en) * 2009-05-01 2010-11-04 Allergan, Inc. Intraocular bioactive agent delivery system with molecular partitioning system
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
KR101763440B1 (ko) 2009-12-03 2017-08-14 옵코 헬스, 인크. 과황산화 이당 제제
WO2011075481A1 (en) 2009-12-16 2011-06-23 Allergan, Inc. Intracameral devices for sustained delivery
KR101911960B1 (ko) 2010-01-22 2018-10-25 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
EP2568986B1 (en) * 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
AU2011298298B2 (en) 2010-09-03 2016-04-21 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9241829B2 (en) 2011-12-20 2016-01-26 Abbott Medical Optics Inc. Implantable intraocular drug delivery apparatus, system and method
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP3517541B1 (en) 2012-05-08 2020-07-15 Nicox Ophthalmics, Inc. Polymorphic form of fluticasone propionate
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9987233B2 (en) * 2013-03-21 2018-06-05 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US9782345B2 (en) 2013-10-17 2017-10-10 Jade Therapeutics, Inc. Ocular composition and method
CN110302138B (zh) 2013-10-31 2022-09-30 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
AU2014348369B2 (en) * 2013-11-15 2020-04-02 Allergan, Inc. Methods of treatment of ocular conditions with a sustained drug delivery implant
CA2950187A1 (en) 2014-05-29 2015-12-03 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11351124B2 (en) 2015-10-27 2022-06-07 Eupraxia Pharmaceuticals Inc. Sustained release of formulations of local anesthetics
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
US11096993B2 (en) 2016-12-08 2021-08-24 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
US11123411B2 (en) * 2016-12-08 2021-09-21 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
BR112020000504A2 (pt) * 2017-07-11 2020-07-14 Sustained Nano Systems Llc esterilização por radiação de formas de dosagem de polímeros hipercomprimidos
WO2023201315A2 (en) * 2022-04-14 2023-10-19 TearClear Corp. Ophthalmic agent in preservative removal device

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE442820B (sv) * 1984-06-08 1986-02-03 Pharmacia Ab Gel av tverbunden hyaluronsyra for anvendning som glaskroppssubstitut
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4851521A (en) * 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
EP0224987B1 (en) * 1985-11-29 1992-04-15 Biomatrix, Inc. Drug delivery systems based on hyaluronan, derivatives thereof and their salts and method of producing same
US5770589A (en) * 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
JP3404557B2 (ja) * 1993-09-30 2003-05-12 グンゼ株式会社 架橋ヒアルロン酸及びこれらの複合材料
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5646136A (en) * 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
JP2000119196A (ja) * 1998-10-07 2000-04-25 Menicon Co Ltd 眼科用薬剤徐放材及びその製造方法
KR100638150B1 (ko) * 1998-12-23 2006-10-26 이데아 악티엔게젤샤프트 생체내에서 국부적인 비침습성 용도로 사용되는 개선된 제제
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
GB0328630D0 (en) * 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
WO2006017347A2 (en) * 2004-07-12 2006-02-16 Allergan, Inc. Opthalmic compositions and methods for treating ophthalmic conditions
NZ562032A (en) * 2005-10-18 2011-11-25 Allergan Inc Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues

Also Published As

Publication number Publication date
WO2009039262A3 (en) 2009-05-07
EP2200581A2 (en) 2010-06-30
CA2700072C (en) 2016-08-09
AU2008302309A1 (en) 2009-03-26
CA2700072A1 (en) 2009-03-26
US20150265633A1 (en) 2015-09-24
WO2009039262A2 (en) 2009-03-26
US20090082321A1 (en) 2009-03-26
JP2015091858A (ja) 2015-05-14
JP2010540447A (ja) 2010-12-24
AU2008302309B2 (en) 2014-09-25
US20110077229A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
BRPI0817200A2 (pt) composições oftálmicas sólida e uso de compostos para fabricação de medicamento
BRPI0820665A2 (pt) compostos de peptidil nitrilas, processos para fabricação dos mesmos, composição farmacêutica, combinação e uso de ditos compostos
BRPI0813105A2 (pt) Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0720124A2 (pt) Composições farmacêuticas e seus métodos de uso.
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
BRPI0810161A2 (pt) Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
CU23871B1 (es) Composiciones y métodos de uso para anticuerpos de dickkopf-1
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0822104A2 (pt) Composições antimicrobianas e métodos para o uso das mesmas
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0913086A2 (pt) Composições antimicrobianas e métodos de uso
BRPI0807487A2 (pt) Uso de antagonistas de il-23 para o tratamento de infecção
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
CR10725A (es) Compuestos de pirazolina y su uso y composiones farmaceuticas
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0810019A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL